Claims for Patent: 7,935,808

Summary for Patent: 7,935,808

Title:	Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells
Abstract:	Compositions and methods comprising recombinant expression vector elements (rEVEs) to enhance the level of expression of recombinant proteins are described. Other compositions and methods for lowering, substantially suppressing, or essentially silencing expression of a recombinant protein are also described.
Inventor(s):	Gion; Wendy R. (Charlton, MA), Carson; Gerald R. (Belmont, MA), Gao; Hong (Allston, MA), Kunes; Yune Z. (Winchester, MA)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	12/079,748
Patent Claims:	1. An isolated recombinant expression vector element (rEVE) polynucleotide molecule comprising a nucleotide base sequence selected from the group consisting of the nucleotide base sequence of SEQ ID NO:1, the nucleotide base sequence of SEQ ID NO:2, a sequence complementary to any foregoing sequence, an expression-enhancing portion of any foregoing sequence, and combinations thereof. 2. The isolated rEVE polynucleotide molecule according to claim 1, wherein the rEVE polynucleotide molecule comprises an expression-enhancing portion of the sequence of SEQ ID NO:2 selected from the group consisting of the sequence of bases 462-2422 of SEQ ID NO:2 and the sequence of bases 1087-2422 of SEQ ID NO:2. 3. A recombinant vector comprising a rEVE polynucleotide molecule as described in claim 1. 4. The recombinant vector according to claim 3, wherein the recombinant vector is a recombinant expression vector. 5. The recombinant expression vector according to claim 4 selected from the group consisting of a recombinant plasmid expression vector, a recombinant eukaryotic viral expression vector, a recombinant bacteriophage expression vector, a recombinant yeast mini-chromosome expression vector, a recombinant bacterial artificial chromosome expression vector, and a recombinant yeast expression plasmid vector. 6. The recombinant expression vector according to claim 4, wherein the recombinant expression vector comprises one or more functional recombinant genes encoding one or more recombinant proteins. 7. The recombinant expression vector according to claim 6, wherein said one or more recombinant proteins is selected from the group consisting of a soluble protein, a membrane protein, a structural protein, a ribosomal protein, an enzyme, a zymogen, an antibody molecule, a cell surface receptor protein, a transcription regulatory protein, a translation regulatory protein, a chromatin protein, a hormone, a cell cycle regulatory protein, a G protein, a neuroactive peptide, an immunoregulatory protein, a blood component protein, an ion gate protein, a heat shock protein, a dihydrofolate reductase (DHFR), an antibiotic resistance protein, a functional fragment of any of the preceding proteins, an epitope-containing fragment of any of the preceding proteins, and combinations thereof. 8. The recombinant expression vector according to claim 7, wherein the antibody molecule is selected from the group consisting of an anti-TNF-.alpha. antibody, an anti-EL-selectin antibody, an anti-IL-13 antibody, and a dual variable domain immunoglobulin molecule. 9. The recombinant expression vector according to claim 8, wherein the anti-TNF-.alpha. antibody is adalimumab. 10. The recombinant expression vector according to any one of claims 4-9, wherein said recombinant expression vector comprises at least one copy of a gene encoding a dihydrofolate reductase. 11. A host cell comprising a vector described in any one of claims 3-9. 12. The host cell according to claim 11, wherein the host cell is a eukaryotic host cell or a prokaryotic host cell. 13. The host cell according to claim 12, wherein the host cell is a eukaryotic host cell selected from the group consisting of a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell. 14. The host cell according to claim 13, wherein the eukaryotic host cell is a mammalian host cell. 15. The host cell according to claim 14, wherein the mammalian host cell is selected from the group consisting of a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK 293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, and an MDCK cell. 16. The host cell according to claim 15, wherein the mammalian host cell is a CHO cell. 17. The host cell according to claim 13, wherein the eukaryotic host cell is a fungal host cell. 18. The host cell according to claim 17, wherein the fungal host cell is selected from the group consisting of Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida. 19. The host cell according to claim 18, wherein the Saccaromyces host cell is an S. cerevisiae host cell. 20. The host cell according to claim 13, wherein the eukaryotic host cell is a protozoan host cell. 21. The host cell according to claim 20, wherein the protozoan host cell is a Leishmania tarentolae host cell. 22. A method of producing a recombinant protein of interest comprising transcribing and translating one or more genes encoding the recombinant protein of interest present on a recombinant expression vector described in any of claims 4-9. 23. The method according to claim 22, wherein said transcribing and translating occur in a cell-free transcription/translation system or in a host cell. 24. The method according to claim 23, wherein said transcribing and translating occur in a host cell. 25. The method according claim 24, wherein said host cell is a CHO host cell. 26. A method of producing a host cell that stably expresses elevated levels of a recombinant protein of interest, comprising: inserting into host cells a recombinant expression vector described in claim 10, growing said host cells in the presence of methotrexate to select for a methotrexate-resistant host cell that expresses the recombinant protein of interest, and isolating said methotrexate-resistant host cell, wherein said isolated methotrexate-resistant host cell expresses the recombinant protein of interest at a level that is higher than that of a methotrexate-sensitive host cell, and wherein said methotrexate-resistant host cell stably expresses an elevated level of the recombinant protein when grown in the presence or in the absence of methotrexate. 27. The method according to claim 26, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 .mu.M. 28. The method according to claim 26, wherein said host cell is a CHO host cell. 29. In a dihydrofolate reductase (DHFR)-methotrexate method for amplifying the expression of a recombinant protein of interest encoded on a recombinant expression vector in a host cell, wherein said recombinant expression vector comprises a gene coding for the recombinant protein of interest and a gene encoding DHFR, the improvement wherein said recombinant expression vector also comprises a rEVE polynucleotide molecule as described in claim 1 or claim 2, wherein growth of host cells containing the expression vector in the presence of methotrexate selects for and produces a methotrexate-resistant host cell that stably expresses the recombinant protein of interest at an amplified level when grown in the presence or in the absence of methotrexate. 30. The method according to claim 29, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 .mu.M. 31. The method according to claim 29, wherein said host cell is a CHO host cell. 32. A method of improving or enhancing the ability of a population of host cells that express a recombinant protein to adapt to growth in the presence of methotrexate comprising the step of: inserting into host cells a recombinant expression vector comprising: a recombinant gene encoding a recombinant protein of interest, a recombinant expression vector element (rEVE) polynucleotide molecule comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, a portion of SEQ ID NO:1, a portion of SEQ ID NO:2, and combinations thereof, and a dihydrofolate reductase (DHFR) gene; wherein a population of the host cells containing the recombinant expression vector has a higher survivability and/or higher growth rate when grown in the presence of methotrexate compared to a population of host cells carrying the same recombinant expression vector lacking the rEVE polynucleotide molecule. 33. The method according to claim 32, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 .mu.M. 34. The method according to claim 32, wherein said host cell is a CHO host cell. 35. A method of producing a methotrexate-resistant host cell that expresses elevated levels of a recombinant protein, comprising: inserting into host cells a recombinant expression vector comprising: a recombinant gene encoding a recombinant protein of interest, a recombinant expression vector element (rEVE) polynucleotide molecule comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, a portion of SEQ ID NO:1, a portion of SEQ ID NO:2, and combinations thereof, and a dihydrofolate reductase (DHFR) gene; growing the host cells in the presence of methotrexate to select for a methotrexate-resistant host cell that expresses the recombinant protein of interest; and isolating said methotrexate-resistant host cell; wherein said isolated methotrexate-resistant host cell expresses the recombinant protein of interest in the presence of methotrexate at a level that is higher than that of a methotrexate-resistant host cell containing an expression vector lacking a rEVE sequence. 36. The method according to claim 35, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 .mu.M. 37. The method according to claim 35, wherein said host cell is a CHO host cell. 38. A method of increasing the number of matrix attachment region (MAR) sequences present in a first nucleic acid molecule comprising inserting into said first nucleic acid molecule a second nucleic acid molecule, said second nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, a portion of SEQ ID NO:1 comprising at least one MAR sequence, SEQ ID NO:2, a portion of SEQ ID NO:2 comprising at least one MAR sequence, and combinations thereof. 39. The method according to claim 38, wherein said first nucleic acid molecule is selected from the group consisting of a vector molecule, a eukaryotic cell chromosome, a eukaryotic viral genome, a prokaryotic cell chromosome, a prokaryotic viral genome, a yeast artificial chromosome, and a bacterial artificial chromosome. 40. The method according to claim 39, wherein said first nucleic acid is a vector molecule. 41. The method according to claim 40, wherein said vector molecule is a recombinant expression vector molecule. 42. The method according to claim 41, wherein said recombinant expression vector comprises one or more functional genes. 43. The method according to claim 42, wherein said one or more functional genes encodes one or more proteins selected from the group consisting of a soluble protein, a membrane protein, a structural protein, a ribosomal protein, an enzyme, a zymogen, an antibody molecule, a cell surface receptor protein, a transcription regulatory protein, a translation regulatory protein, a chromatin protein, a hormone, a cell cycle regulatory protein, a G protein, a neuroactive peptide, an immunoregulatory protein, a blood component protein, an ion gate protein, a heat shock protein, a dihydrofolate reductase (DHFR), an antibiotic resistance protein, a functional fragment of any of the preceding proteins, an epitope-containing fragment of any of the preceding proteins, and combinations thereof. 44. The method according to claim 43, wherein said antibody molecule is selected from the group consisting of an anti-TNF-.alpha. antibody, an anti-EL-selectin antibody, an anti-IL-13 antibody, and a dual variable domain immunoglobulin molecule. 45. The method according to claim 44, wherein the anti-TNF-.alpha. antibody is adalimumab. 46. A method of lowering expression, substantially suppressing expression, or essentially silencing expression of a recombinant protein from an expression vector comprising: inserting into an expression vector comprising one or more recombinant genes encoding one or more recombinant proteins, a nucleic acid molecule comprising the nucleotide base sequence of bases 1-461 of SEQ ID NO:2 or of bases 1-1086 of SEQ ID NO:2. 47. The method according to claim 46 further comprising: inserting said expression vector into a host cell.

Details for Patent 7,935,808

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2027-03-30
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2027-03-30
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2027-03-30